Dr Reddy's Gains on Wegovy Plans

  Published 11 months ago

Dr Reddy’s rises 2.4% on plans to launch generic Wegovy in 87 nations; analysts boost earnings forecasts on growth outlook.

  • Targets early Semaglutide launch in Canada, global rollout before March 2026 patent expiry; low competition expected.
  • Jefferies, Goldman hike FY26–28 EPS forecasts; also sees growth from Abatacept IV launch in 2027.
  • Q1 profit slightly misses on U.S. pricing pressure; stock still down ~10% YTD despite 11.4% revenue growth.

You might like these

Shriram Finance Jumps on Q1 Optimism

Schneider India CFO Resigns

Mankind Pharma Expands to Sri Lanka

Trump Targets India Over Russian Oil Trade

Cabinet Hikes PMKSY Outlay by Rs 1,920 Cr

Lemon Tree Opens New Hotel in Phases

JTL Profit Falls Despite Higher Sales

News that matters the most ⚡